– Ireland’s Centre For AI

Projects

2DBioPAD

Project Status: Live Project

EU Programme: HORIZON.2.4 – Digital, Industry and Space

Start Date: 01/10/2023

Finish Date: 30/09/2027

Project Website: https://2d-biopad.eu/

 

This project is made up of 11 partners including academic, technical and healthcare groups.

2D-BioPAD aims to introduce a fast, cost-effective, non-invasive, reliable, digitally and graphene-enabled Point-of-Care (PoC) in-vitro diagnostics (IVD) system. This innovative solution supports early diagnosis and progression monitoring of Alzheimer’s Disease (AD) directly at primary healthcare settings, enhancing patient care and enabling timely interventions for better health outcomes in the community.

Currently there is no single test for AD, diagnosis relies on combinations of neurological exams, imaging and invasive tests. 2D‑BioPAD aims to change this by combining 2D materials, nanomaterials and aptamer technologies to detect up to five AD biomarkers from blood samples in real time.

 

Objectives

  • Introduce an affordable PoC IVD system for early AD diagnosis in primary healthcare settings.

  • Enhance Europe’s industrial standing in 2D materials for biomedical devices, aligning with the Graphene Flagship Initiative’s (GFI) goals

  • Prioritise safety, ethics, and regulatory compliance

  • Conduct proof-of-concept clinical pilots to validate the approach

  • Utilise CRM-free graphene sensors to enhance diagnostics and disease progression monitoring.

  • Foster synergies, knowledge exchange, and sustainable result exploitation

Technical Innovations

Graphene‑enabled biosensing – The system leverages graphene’s unique electrical and mechanical properties together with nano and DNA technologies to enhance biocompatibility, stability and sensitivity. This allows simultaneous identification and quantification of up to five AD biomarkers.

User‑friendly digital interface – Health‑care professionals receive key metrics and insights via a simple digital interface, making the PoC tool practical for primary care.

AI‑enhanced analysis – Artificial intelligence is used to optimise the design, training and implementation of the system, improving accuracy and reducing false positives. CeADAR leads the training and optimisation of these AI models.

Clinical validation – Two pilot studies in Finland, Greece and Germany will test the system’s safety, ethical compliance and performance. Ethical‑by‑design principles are incorporated from the outset to maximise acceptance in healthcare

Visit the ADT4Blue Website